Skip to main content
Premium Trial:

Request an Annual Quote

ABI Reports 4-Percent Revenue Growth in Fiscal Q2; RT-PCR Sales Surge as Sequencing Suffers

NEW YORK, Jan. 25 (GenomeWeb News) - Applied Biosystems reported a 4-percent increase in total revenue for its second quarter of fiscal 2006, the company said today.


ABI had total revenues of $481 million for the three months ended Dec. 31, 2005, compared to $463 million for same period one year ago.  The company reported solid growth in its RT-PCR and Applied Genomics unit, where revenues grew 10 percent to $147 million. Revenue for its mass spectrometry segment grew  5 percent to $119 million year over year.


The company's DNA-sequencing segment did not fare as well, sliding more than 1 percent to $141 million. ABI said that it expected revenue growth in the real-time PCR/applied genomics and mass spec product categories to continue, and anticipated a further decline in its DNA sequencing segment.


ABI also reported R&D expenses of $45 million for the quarter, a slight decrease from $47 million a year ago, a decrease ABI attributed to a realignment of its R&D investments.


Net income fell to $31 million from $73 million for the same period last year.


ABI said it expects its growth to be in the low to mid single-digits for the remainder of FY 2006.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.